
Late-breaking ESMO 2026 data show PFS gains with 3 antibody-drug conjugates, a 6-year OS benefit with adjuvant ribociclib, and no OS gain with pembrolizumab.
Eleftherios Mamounas, MD, MPH, discusses locoregional recurrence and tailoring radiotherapy following neoadjuvant chemotherapy.
Eleftherios Mamounas, MD, MPH, medical director, Comprehensive Breast Program, University of Florida Health Cancer Center, discusses locoregional recurrence and tailoring radiotherapy following neoadjuvant chemotherapy.
<<<






